Vericel delivered a solid second quarter in 2025, achieving record total revenue and MACI revenue. The company saw substantial growth in adjusted EBITDA and improved gross margin, alongside positive trends in key performance indicators for its MACI Arthro launch and burn care products.
Total net revenue increased by 20% to $63.2 million, driven by strong performance across all product lines.
Gross margin improved significantly by over 400 basis points to 74%, indicating enhanced profitability.
Adjusted EBITDA surged by 112% to $13.4 million, with the adjusted EBITDA margin expanding to 21%.
The company maintained a strong cash position with approximately $164 million in cash and investments and no debt as of June 30, 2025.
Vericel reaffirmed its full-year 2025 financial guidance, expecting continued strong revenue growth and profitability.
Visualization of income flow from segment revenue to net income